Parvovirus B19 infection in a child with acute lymphoblastic leukemia during induction therapy.
Immunocompromised children, including those undergoing chemotherapy treatment of malignant disease, are at particular risk for infection with parvovirus B19. However, these patients' attenuated immune responses may obscure the serologic and clinical manifestations of the infection. The authors describe a patient undergoing induction therapy for acute lymphoblastic leukemia whose parvovirus B19 infection was identified by the incidental detection of giant pronormoblasts and absence of normal mature erythroid precursors, characteristic of parvovirus infection, on a routine bone marrow examination. Intravenous immunoglobulin was administered and the patient's aplastic anemia resolved completely within 3 weeks. This highlights the importance of alertness to the possibility of parvovirus infection in children with cancer.
McNall
R Y
RY
Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA.
Head
D R
DR
Pui
C H
CH
Razzouk
B I
BI
D000741:Anemia, Aplastic / Q000209:etiology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D001803:Blood Transfusion; D002051:Burkitt Lymphoma / Q000150:complications* / Q000188:drug therapy; D002648:Child; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage; D010322:Parvoviridae Infections / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D016732:Parvovirus B19, Human / Q000302:isolation & purification*; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D016756:Immunoglobulins, Intravenous; D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin